Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

416 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists
Duchesne C, et al. Dig Liver Dis 2014. Among authors: Faure P. PMID 24809234
Significantly fewer ulcerative colitis patients were treated with anti-tumour necrosis factor therapy than Crohn's disease patients (18.9% vs. 38.9%; p<0.0001). ...
Significantly fewer ulcerative colitis patients were treated with anti-tumour necrosis factor therapy than Crohn's disease patients (18.9% v …
Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey
Oussalah A, et al. Aliment Pharmacol Ther 2009 - Clinical Trial. Among authors: Faure P. PMID 19764940
In luminal Crohn's disease, 97% of hospital practitioners introduced infliximab as first-line anti-TNF therapy vs. 78% of physicians with nonhospital activity (P = 0.002); only 22.5% of gastroenterologists opted for adalimumab as first-line therapy. ...
In luminal Crohn's disease, 97% of hospital practitioners introduced infliximab as first-line anti-TNF therapy vs. 78% of physicians with no …
Rapid-onset febrile dermatosis
Décisier M, et al. Gut 2009. Among authors: Faure P. PMID 19091830
Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study
Briot C, et al. J Crohns Colitis 2019 - Clinical Trial. Among authors: Faure P. PMID 30785181
The preparation did not reach the Boston's score efficacy outcome in the PEG-4L group in 51.2% of the patients [p = 0.0011]. ...Tolerability, as assessed by the patients' VAS, was significantly better for both Pico and PEG-2L compared with PEG-4L, and better for Pico compared with PEG-2L [p = 0.008; p = 0.0003]. ...
The preparation did not reach the Boston's score efficacy outcome in the PEG-4L group in 51.2% of the patients [p = 0.0011]. ...Toler …
416 results
Jump to page
Feedback